儿童呼吸支持一线辅助方案:FIRST-ABC 试验的统计与卫生经济学分析计划
FIRST-ABC 试验包含两项实用性、多中心、平行组、非劣效随机临床试验,评估危重儿童需要无创呼吸支持时一线使用高流量鼻导管(HFNC)相较持续气道正压(CPAP)的临床非劣效性。本文在招募和数据收集完成前预先设定主要和次要结局、数据收集与安全监测方法,以及统计和卫生经济学分析方案。主要临床结局为脱离呼吸支持的时间,主要效应估计为校正风险比并报告 95% 置信区间。
要点
- 主要结局为脱离呼吸支持时间,效应量为校正风险比及 95%CI。
- 敏感性分析将用开始撤除无创呼吸支持的时间重复主要分析。
- 卫生经济学分析按意向性治疗原则报告至 6 个月的增量成本与 QALY。
核心结论
- FIRST-ABC 试验将在两项共享基础设施的平行试验(step-up RCT 与 step-down RCT)中评估 HFNC 相较 CPAP 的非劣效性。
- 研究者在试验完成前制定预先设定的统计与卫生经济学分析计划,以减少分析偏倚。
研究设计与样本
- 两项实用性、多中心、平行组、非劣效随机临床试验,纳入需要无创呼吸支持的危重儿童。
- 统计分析计划由主要研究者和统计学家设计,定义主要和次要结局并概述数据收集与安全监测方法。
主要发现
- 主要临床结局为脱离呼吸支持的时间,主要效应估计为校正风险比,报告 95% 置信区间。
- 敏感性分析将用开始撤除无创呼吸支持的时间重复主要分析。
- 将进行亚组分析,检验分配治疗组效应与预先设定基线协变量之间的交互作用。
- 卫生经济学分析遵循意向性治疗原则,报告至 6 个月的平均(95% 置信区间)增量成本、质量调整生命年(QALYs)和成本效果。
- 所有分析将在两项试验中分别进行,任何结果均不予合并。
关键数值与推荐
- 主要效应估计为校正风险比,报告 95% 置信区间。
- 卫生经济学分析报告至 6 个月的平均(95% 置信区间)增量成本、QALYs 和成本效果。
- 试验注册号 ISRCTN60048867,注册日期 2019 年 6 月 19 日。
临床怎么用
- 该分析计划为 HFNC 与 CPAP 作为儿童一线无创呼吸支持的比较提供预设的统计与经济学评价框架。
局限性
- 本文为分析计划,尚未报告试验结果。
- 两项试验结果将分别分析且不合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The FIRST-ABC trial comprises of two pragmatic, multicentre, parallel groups, non-inferiority randomised clinical trials designed to evaluate the clinical non-inferiority of first-line use of high flow nasal cannula (HFNC) to continuous positive airway pressure (CPAP) in critically ill children who require non-invasive respiratory support (NRS). OBJECTIVES: To describe the pre-specified statistical and health economic analysis for the FIRST-ABC trial before completion of patient recruitment and data collection. METHODS: The statistical analysis plan was designed by the chief investigators and statisticians. We define the primary and secondary outcomes, summarise methods for data collection and safety monitoring, and present a detailed description of the planned statistical and health economic analysis. RESULTS: The primary clinical outcome is time to liberation from respiratory support. The primary effect estimate will be the adjusted hazard ratio, reported with a 95% confidence interval. As a sensitivity analysis, the primary analysis will be repeated using time to start weaning of NRS. Subgroup analyses will be performed to test for interactions between the effect of allocated treatment group and pre-specified baseline covariates. The health economic analysis will follow the intention-to-treat principle and report the mean (95% confidence interval) incremental costs, quality-adjusted life years (QALYs) and cost-effectiveness up to 6 months. All analyses will be performed separately for each of the two trials, and any results will not be combined. CONCLUSION: The FIRST-ABC trial will assess the non-inferiority of HFNC compared to CPAP in two parallel trials with shared infrastructure (step-up RCT and step-down RCT). We have developed a pre-specified statistical and health economics analysis plan for the FIRST-ABC study before trial completion to minimise analytical bias. TRIAL REGISTRATION: ISRCTN ISRCTN60048867 . Registered on 19 June 2019.
引用
- Orzechowska I, Sadique MZ, Thomas K, et al. First-line support for assistance in breathing in children: statistical and health economic analysis plan for the FIRST-ABC trial. Trials. 2020. PMID: 33129360. doi:10.1186/s13063-020-04818-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。